Applied Clinical Trials
Allison Burmeister discussed the average cost increase based on the per patient cost in a clinical trial during her presentation at the ExL Pharma C.R.O.W.N. Event.
"Clinical trials are labor intensive," emphasized Allison Burmeister, Senior Analyst, Clinical Business Operations for Janssen Alzheimer Immunotherapy R&D, during her presentation last month at the ExL Pharma C.R.O.W.N. Event, when presenting her case study on "Mitigating Risks and Variance When Budgeting and Contracting for a Complex Global Clinical Trial."
Burmeister's presentation began with an outline of the average cost increase based on the per patient cost in a clinical trial, from which she gleaned from a July 2011 article on Pharmalot that was based on a Cutting Edge Information survey. Those costs per patient are as follows in 2011: Phase I: $21,883; Phase II: $35,070; Phase IIIa: $47,523; Phase IIIb: $47,095; and Phase IV: $17,042.
That snapshot set the stage for Burmeister's case study, of which she referred to a 210 site, 1,670 subject, four-year long, 14 country, Phase III study. The average study start-up costs were budgeted at $4.4M—and this is even before a trial starts to enroll.
Burmeister urged the audience to consider that no scope or budget detail is too small because the chance for it not to be included could significantly shift the variance of a budget.
For example, screen fail rates. For this particular trial, Burmeister went to the project managers and the sites to ask how many patients they thought wouldn't pass the screen and came up with a 64%. So if a total of 7,200 potential subjects fail the screen, the cost would be $15 million. Said Burmeister, "If that is not factored into the budget, that could be a considerable variance to cost."
Other key factors beyond the screen fail rate that impact the trial include the number of subjects, the enrollment rate over the length of the trial (has to be factored over the number of years), drop-out rate, number of sites, the site activation rate, and the schedule of assessments. The schedule of assessments, again should be extremely detailed so that the number of procedures per patient are truly counted into the budget.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.